Topic:

Venture Capital

Latest Headlines

Latest Headlines

Wellcome ponies up $20M to kick-start an Oxford spinoff

With the help of Syncona, the Wellcome Trust's venture arm, Oxford University spinout NightstaRx has $20 million and a plan to develop gene therapies for degenarative eye conditions.

Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush

The big question at the beginning of this year was whether investors would continue to eagerly buy up shares offered in new biotech IPOs, continuing the burst of new offerings that injected billions of dollars into the industry last year. As of today, the answer--for at least a few select biotechs--is a boisterous "yes."

UPDATED: Third Rock backs $14M round for Igenica's cancer-fighting antibodies

The antibody upstart Igenica has rounded up $14 million in venture cash to move its lead drug into the clinic. The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures all participated in the round.

Q4 venture haul pushes 2013 biotech investing past $4.5B

U.S. biotech companies attracted a bountiful $1.3 billion venture haul in the fourth quarter of 2013, pushing the total for the year to $4.53 billion--well ahead of 2012's mark of $4.19 billion and a hopeful sign of continued activity headed into 2014.

The dethroned 'King of Biotech' will stay exiled in prison

David Blech, the long dethroned "King of Biotech," will spend the next three years in a low-security prison in Fort Dix, NJ, after a federal appeals court tossed out claims that the judge presiding over his case had been biased against him.

Amazon's Jeff Bezos bets some of his personal cash on Juno's immunotherapy tech

Amazon founder and new media mogul Jeff Bezos is investing a bit of his personal fortune in Seattle-based Juno Therapeutics, a biotech startup that's been making some big waves in the immunotherapy world.

Merck invests in an FDA-cleared mobile diabetes management business

Since setting up shop in 2006, WellDoc has financed development of its mobile diabetes management tool through debt and angel investment, snagging itself the input of pharma veterans in the process. Now, it has landed its first round of institutional investment, with Merck Global Health Innovation Fund and others committing $20 million.

Amgen spinoff Atara cranks its Series B up to $52M

California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen spinoff $52 million in Series B funds to support its programs in kidney disease and oncology.

Upstart biotech nabs Roche drug, $22.5M A round

Canadian biotech Clementia Pharmaceuticals has closed a $22.5 million A round led by OrbiMed and licensed in a drug from Roche it plans to develop for a rare bone disorder called fibrodysplasia ossificans progressiva.

Billionaire backs new program for a pioneering Alzheimer's vaccine from AC Immune

German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer's programs.